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and communication they enable. We will also look at the practicalities of each
method, and their relative merits and drawbacks and how these can be addressed
to maximise their usefulness in refining and improving the translation.
CONCLUSIONS: We will argue that both methods are beneficial in particular cir-
cumstances, and will explore the situations in which each one would be the most
appropriate.
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WHAT EPRO MODALITY IS APPROPRIATE FOR YOUR STUDY?
O’Gorman HJ1, Ross J2, Peck R2, Ross E2
1Almac Group, Craigavon, UK, 2Almac Clinical Technologies, Souderton, PA, USA
OBJECTIVES: To help clarify which ePRO modality (IVR, IWR, Handheld) is appro-
priate for specific studies through providing three examples of diary requirements
and appropriate modalities. Emphasize making this decision early in the planning
process.METHODS: Examples for three scenarios requiring patients to record their
PRO data electronically were drawn up based on experience to illustrate how mak-
ing appropriate modality choices can minimize patient burden and reduce costs.
Scenario One - 10,000 patient global vaccine study. Scenario Two – 500 patient
global study, daily diary having 40 questions with more than 5 response options.
Scenario Three – 50 GI patients to record their PRO data episodically using a VAS
scale daily for over a year. RESULTS: Scenario One – Appropriate Choice IVR: It is
expensive and logistically challenging for Sponsors to deploy 10,000 PDAs. Using
the IVR global network in place would reduce cost and logistics for the Sponsor and
sites. Scenario Two – Appropriate Choice IWR: When patients are provided more
than 5 response options in a lengthy questionnaire, an IWR would be better since
response options are visual. IWR would be better than PDA given the sample size
and logistics. Scenario Three- Appropriate Choice  PDA: A PDA would be most
convenient for the patient since they are providing data daily for over a year. PDA
is best for VAS scales since the size of the screen can be controlled. CONCLUSIONS:
There is overlap in deciding which ePRO modality to use for a particular clinical
study. It is critical to decide on the modality early when assembling the protocol, so
all points can be considered. Looking at the diary requirements (frequency, length,
access) for the study will help the Sponsor to decide which modality is best. Reduc-
ing patient and site burden will allow for greater compliance.
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OUTCOME MEASURES HIERARCHY FOR ATTENTION-DEFICIT HYPERACTIVITY
DISORDER
Hormaechea-Beldarrain JA1, Prieto L2
1Hospital Quiron Bizkaia, Erandio, Spain, 2London School of Hygiene and Tropical Medicine,
London, UK
OBJECTIVES: Attaining good patient health outcomes is the underlying purpose of
any health care intervention, including drug therapy. METHODS: The outcome
measure is the basis for evaluating the quality of health services, and a key element
in determining the value of health interventions since the value of health care is
defined as outcomes relative to cost. According to Porter (2010), value improvement
starts with defining and measuring the total set of outcomes for a medical condi-
tion and determining the major risk factors. Porter has provided a challenging
framework for identifying the full set of outcomes for any medical condition: the
outcome measures hierarchy (OMH). RESULTS:According to the OMH the full set of
outcomes for any medical condition, and its treatment, can be conveyed in a three-
tiered hierarchy. Each tier of the hierarchy contains two broad levels, each of which
involves one or more distinct outcome dimensions. Each medical condition should
have its own outcome measures. Measurement efforts should begin with at least
one outcome dimension at each tier, and ideally at each level. Possible outcome
dimensions for Attention-Deficit Hyperactivity Disorder (ADHD) are explored and
discussed according to Porter’s OMH. ADHD is a frequent neurobehavioral disorder
that is characterised by inattention, hyperactivity and impulsivity. ADHD is asso-
ciated with considerable social, family, behavioural and cognitive dysfunction, and
is comorbid to depression, bipolar disorder, anxiety, and drug use. Specific dimen-
sions proposed are aimed at capturing particular aspects of patients affected by
ADHD. For each dimension, success is measured with several clinical and patient
reported metrics. Tier 1 of the OMH is the patient’s health status achieved or
retained after a health intervention (clinical or drug therapy). CONCLUSIONS: Tier
2 regards the process of recovery and the eventual disutility of the treatment pro-
cess. Tier 3 concerns the sustainability of health.
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MEASURING RELATIVE EFFECTIVENESS IN EUROPE: AS IN THE USA, HERE TOO,
IT IS TIME TO TURN THE QALY PAGE
Prieto L
European Medicines Agency, London, UK
OBJECTIVES: The recently enacted Patient Protection and Affordable Care Act in
the United States of America (USA) has created a Patient-Centered Outcomes Re-
search Institute to conduct comparative effectiveness research, but has prohibited
this institute from developing or using cost-per-QALY thresholds. METHODS: In
reaction to this new legislation some authors, from both continents, have insisted
that QALYs provide a convenient yardstick for measuring and comparing health
outcomes of varied interventions across diverse diseases and conditions. Such
arguments in defense of QALYs are erroneous. While it is true that QALYs are
internationally recognized as the standard metric of the value of health outcomes,
this acknowledgement is, unfortunately, not deserved. RESULTS: The problem lies
in the QALY calculation (i.e. Utility x Time). While Time is expressed in a ratio scale
with a non-arbitrary zero value, Utility is defined as an interval scale with an
arbitrary zero point (i.e. death). Permissible arithmetic operations on interval
scales are limited: addition and subtraction are allowed, but multiplication and
division are not permitted because the absence of an absolute zero. Consequently,
the resulting QALY values are not expressed in the same units as the Time scale,
preventing any meaningful conclusion on its application to comparative clinical
effectiveness research. CONCLUSIONS: Although we do not know the exact rea-
sons why the Patient Protection and Affordable Care Act bans the use of cost per
QALY in the USA, the initiative should be celebrated, not criticized, and certainly
copied in Europe as well.
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BURDEN OF HOSPITALIZATION IN PATIENTS WITH ADVANCED LUNG CANCER
IN FRANCE AND GERMANY
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OBJECTIVES: To assess the burden of hospitalization in advanced lung cancer pa-
tients in France and Germany. METHODS: Oncologists (N80) and pulmonologists
(N40) actively involved in management of Non small cell lung cancer (NSCLC) in
France and Germany were invited to participate in a lung cancer disease specific
program. Each consenting physician was asked to complete patient record forms
for the next 10 advanced (stage IIIB/IV) lung cancer patients seen in their practice.
The study period extended from July to October 2010. Data on hospitalization over
the past year was provided by the physicians using the patient chart records. The
primary reason of hospitalization and the length of stay (LOS) were reported.
RESULTS: Majority of the patients (N1213) were male (68%), Caucasian (92%),
Stage IV (89%), currently on first line therapy (51%) with an average age of 63 years.
Hospitalization records were obtained for 93% (n1133) of the patients among
which 30% (n341) of the patients had one or more hospitalization events in the
previous year with an average (SD) LOS of 10 (8) days. The primary cause reported
for the 449 hospitalization events were disease symptoms (44%), surgery (20%) and
therapy side effects (17%). The LOS for surgery related hospitalization (n89)
ranged from 1-20 days (mean: 8 days). Among patients hospitalized for disease
symptoms (n197) the most frequently reported primary causes were dyspnea
(23%), cough (10%) and pain (11%) with average LOS of 13, 12 and 8 days respec-
tively. Among patients hospitalized for side effects (n75), anemia (24%), febrile
neutropenia (8%), febrile aplasia (8%) were most frequently reported with average
LOS of 4 days. CONCLUSIONS: Burden of hospitalization due to disease symptoms
and treatment related side effects is significant in France and Germany. Innovative
therapies effective in alleviation of symptoms and side effects could help signifi-
cantly in decreasing hospitalization costs.
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A RETROSPECTIVE LONGITUDINAL STUDY OF TREATMENT PATTERNS AND
OUTCOMES AMONG PATIENTS WITH UNRESECTABLE STAGE IIIC/IV
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OBJECTIVES: Unresectable metastatic melanoma patients (stages IIIc/IV) have a
poor prognosis. Recent improvements in survival have been attributed in part to
earlier detection and investigational therapies, however melanoma is considered
incurable if it becomes metastatic. No information about treatment patterns for
unresectable melanoma in Canada has been published. Objectives of this study
were to describe disease characteristics, treatment patterns, health outcomes, and
resource utilization for Canadian unresectable melanoma patients treated outside
randomized clinical trials [RCT]. METHODS: Charts of melanoma patients at seven
Canadian centres were screened for eligibility. Unresectable melanoma charts
then selected consecutively in reverse chronological order from January 2009 until
target number (n250) exceeded. Data on patient and disease characteristics,
treatments (across three lines), adverse event management, health outcomes and
resource utilization were then extracted from charts of patients with at least two
months of follow-up, from diagnosis until censoring (June 2010 or death). RESULTS:
Of 1426 melanoma patient charts reviewed, 262 (18%) were for unresectable mela-
noma patients, 16% (43/262) of which were first diagnosed in an advanced stage.
Overall, 10% (26/262) participated in an RCT during the follow-up period and 60%
(156/262) received systemic therapy outside an RCT. In the latter group, responsive-
ness to therapy was low; only 20% (26/132) on first-line and 16% (9/58) on second-
line therapy experienced complete or partial response. On first-line therapy, 40%
(53/132) experienced adverse events requiring medical management and 18% (24/
132) were hospitalized during treatment; corresponding figures for second-line
were 38% (22/58) and 24% (14/58) respectively. CONCLUSIONS: This study charac-
terizes treatment patterns and provides quantitative estimates of resource utiliza-
tion for unresectable melanoma patients across Canada. Extant systemic treat-
ments are associated with poor response and considerable resource utilization.
This study quantifies the grim prognosis faced by advanced melanoma patients in
Canada receiving currently available treatments.
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CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL
CANCER
Ubago R1, Castillo MA
1, Flores S2, Rodriguez R1, Beltran C1
1
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OBJECTIVES: To evaluate the efficacy and safety of cetuximab in combination with
chemotherapy vs. chemotherapy alone for the first-line treatment of metastatic
colorectal cancer (mCRC), in patients with KRAS wild-type tumours. METHODS:
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Two systematic reviews of literature have been conducted. One focused on the
efficacy, identifying health technology agencies reports, meta-analysis, systematic
reviews, and randomized controlled trials (RCTs). The safety systematic review
included the previous designs plus observational studies. In the latter review, stud-
ies in subsequent lines of treatment were considered. Searches were done in MED-
LINE, EMBASE, CRD, and the Cochrane Library until the 8th of June. The quality
assessment of the studies was done with the SIGN and CASPe tools. Two authors
independently selected the studies, assessed the quality, and performed the data
extraction, with disagreements resolved by a third reviewer until consensus was
obtained. RESULTS: In the efficacy systematic review, three RCTs were included.
The chemotherapy in one of these trials was FOLFIRI, in another trial FOLFOX-4,
and in the other one was oxaliplatin and fluoropyrimidine chemotherapy. In the
safety systematic review, five RCTs (3 studies in first-line, one study in second-line
and another with cetuximab in monotherapy in subsequent lines), and an obser-
vational study were considered. Cetuximab in combination with FOLFIRI improved
overall survival (OS), resection rate, progression free survival (PFS) and overall
tumour response rate (RR). Whereas, an increase in terms of OS was not observed
with cetuximab in combination with oxaliplatin based regimen, and different re-
sults were obtained in PFS. The only benefit observed with the later regimen was in
the RR. In terms of safety, cetuximab increased grade 3 or 4 skin toxicity.
CONCLUSIONS: The benefit of the addition of cetuximab to standard therapy for
previously untreated mCRC, KRAS wild-type patients differs depending on the
chemotherapy associated, with an improvement in all the outcomes when FOLFIRI
is used.
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EFFECT OF ANTIEMETIC PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED
NAUSEA AND VOMITING WITH 5-HT3 RECEPTOR ANTAGONISTS IN PATIENTS
WITH LYMPHOMA
Lin SJ1, Hatoum HT2, Balu S3
1University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA, 2Hind T. Hatoum &
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OBJECTIVES: 5-hydroxytryptamine3 receptor antagonists (5-HT3 RAs) are used for
prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This study
compared the risk of severe CINV associated with hospitalization or emergency
room admission among patients with lymphoma initiated and maintained on
palonosetron versus the other 5-HT3 RAs (granisetron, ondansetron, and
dolasetron).METHODS:Adult patients diagnosed with lymphoma and treated with
cyclophosphamide were selected from PharMetrics claims data (2005-2009). Other
inclusion criteria were continuous patient enrollment for at least6 months before
the initial diagnosis and receipt of 5-HT3 RA for CINV prevention on the day of
cyclophosphamide treatment (index date). CINV was identified by ICD-9-CM claims
for nausea, vomiting, and/or dehydration. Risk of CINV during the follow-up period
of 6 months from index date was assessed using multiple regression models, con-
trolling for age, gender, Charlson Comorbidity Index (CCI), and total dose of
cyclophosphamide. RESULTS: A total of 2609 patients were studied. Palonosetron
patients (n979; 37.5%) were older than the other 5-HT3 RAs (62.1 13.6 vs. 59.0
14.1 years, p0.0001), with similar CCI and gender. During follow-up, palonosetron
patients received more cyclophosphamide dose in significantly fewer CT days
(586 mg; p0.0005 and -0.73 days, both p0.0001), and had fewer patients expe-
riencing unadjusted severe CINV (7.3% vs. 10.4%, p0.007) as compared to the other
5-HT3 RA patients. Multiple regressions found that palonosetron group (versus the
other 5-HT3 RA group) experienced fewer CINV claims (0.47 less; p0.0253), fewer
CINV days (48% less; p0.0006), and a 34% lower severe CINV risk (Odds Ratio0.66;
p0.006). CONCLUSIONS: Patients in palonosetron group received higher CT dose
within fewer CT days and experienced significantly lower risk for potentially costly
CINV events than patients on other 5-HT3-RA-based antiemetic prophylaxis. Fur-
ther studies on the clinical and economic impact of the choice of 5-HT3-RA for CINV
prophylaxis in patients with lymphoma are needed.
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REDUCED RISK OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN
PATIENTS WITH CANCER TREATED WITH HIGHLY EMETOGENIC
CHEMOTHERAPY AND ANTIEMETIC PROPHYLAXIS WITH PALONOSETRON
Schwartzberg L1, Jackson J2, Jain G2, Balu S3
1Accelerated Community Oncology Research Network, Memphis, TN, USA, 2Xcenda, LLC., Palm
Harbor, FL, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
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OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
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THE INCIDENCE AND OUTCOME OF FEBRILE NEUTROPENIA IN DIFFERENT
CHEMOTHERAPY REGIMENS FOR CANCER PATIENTS IN BELGIUM
Chevalier P1, Lamotte M2, Malfait M3, Marciniak A4
1IMS Health, Vilvoorde, Belgium, 2IMS Consulting Group, Vilvoorde, Belgium, 3AmGen sa/nv,
Brussels, Belgium, 4Amgen Ltd, Uxbridge, UK
OBJECTIVES: The incidence of febrile neutropenia (FN) depends on the cancer type
and the chemotherapy regimen used. In Belgium, reimbursement of granulocyte-
colony stimulating factors (G-CSF) in primary prophylaxis against FN is limited to 4
indications. This study aimed to provide real-life information on the incidence and
impact of FN in chemotherapy-cancer combinations excluded from G-CSF primary
prophylaxis reimbursement. METHODS: Based on ICD-9 code and drug name all
chemotherapy-cancer combinations with at least one patient having an ICD-9 code
corresponding to neutropenia (288.0) and/or fever (780.6) and where G-CSF primary
prophylaxis was not reimbursed, were retrieved from the IMS Hospital Disease
database for the period 2005-2008. This database includes longitudinal (per calen-
dar year) information on diagnoses and drugs prescribed in about 34% of all Belgian
hospital beds. Incidence of FN (cases of FN with chemo-cancer combination di-
vided by total number of patients with this chemo-cancer combination), mortality
in patients with and without FN and impact of FN on subsequent chemotherapy
treatment decisions were assessed. RESULTS: Among the 25,544 patients at risk,
3,191 (13%) had at least one FN episode. Highest incidence rates were found in
combinations of cisplatin-containing regimens with head and neck (71/287, 25%),
stomach (24/110, 22%) and esophagus (36/202, 18%) cancers, lung cancers treated
with cisplatin-etoposide (52/292, 18%) or carboplatin-etoposide (102/659, 16%) reg-
imen and multiple myeloma treated with doxorubicin-vincristine regimen (26/152,
17%). Overall, 50% of first FN episodes occurred during cycle 1. Of the 3191 FN
patients 11% died, 24% switched chemotherapy regimen and 22% stopped treat-
ment during the cycle with FN. FN occurred subsequently in 27% of 1367 patients
continuing the same regimen. CONCLUSIONS: This study suggests clinically sig-
nificant FN-incidence is associated with chemotherapy regimens where G-CSF pri-
mary prophylaxis is not reimbursed in Belgium, which may lead to negative out-
comes in terms of mortality and treatment disruption.
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INCIDENCE, PREDICTIVE FACTORS, AND INFECTION COMPLICATIONS OF
PROLONGED NEUTROPENIA IN R-CHOP/CHOP TREATED DIFFUSE LARGE B-CELL
LYMPHOMA PATIENTS
Zhou KR1, Kei KM1, Ng HM1, Wong RS2
1The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 2Prince of Wales Hospital,
Shatin, N.T., Hong Kong
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